Jury still out on holding GLP-1s prior to endoscopy as new research continues to emerge (Healio)

The FDA has approved a generic version of liraglutide (Victoza) for managing blood sugar in type 2 diabetes patients aged 10 and older, enhancing access to affordable GLP-1 medications amid shortages. Manufactured by Hikma Pharmaceuticals, this once-daily injectable complements diet and exercise and aligns with the FDA’s efforts to promote competition and accessibility for complex drug products.